中国1996—2014年肺癌经济负担研究系统评价  

Economic burden of lung cancer in China's Mainland,1996-2014: a systematic review

作　　者：石春雷 娄培安[2] 石菊芳 黄慧瑶[3] 李江[3] 岳馨培 王乐[3] 董宗美[2] 陈培培 张盼 赵春艳 李放 周金意[5] 代敏 

机构地区：[1]徐州医科大学公共卫生学院流行病学与卫生统计教研室,江苏徐州221004 [2]徐州市疾病预防与控制中心慢性非传染性疾病防治科 [3]国家癌症中心/中国医学科学院肿瘤医院城市癌症早诊早治项目办公室 [4]国家癌症中心/中国医学科学院肿瘤医院胸外科 [5]江苏省疾病预防与控制中心慢性非传染性疾病防治所

出　　处：《中国公共卫生》2017年第12期1767-1774,共8页Chinese Journal of Public Health

基　　金：国家自然科学青年基金(81402740;81773521;81602930);科技部重大慢性非传染性疾病专项研究(2017YFC1308700;2017YFC1308705);教育部高等学校博士学科点专项科研基金(20131106120014);国家城市癌症早诊早治项目

摘　　要：目的探讨中国1996—2014年肺癌经济负担研究状况,为肺癌防控措施相关评价及卫生决策提供参考依据。方法以癌症、经济负担、费用等为检索词,检索中国知网、万方和Pub Med数据库1996年1月1日—2014年12月31日发表的关于中国肺癌经济负担的文献,再按非肺癌相关文献等标准进行排除,对最终纳入的32篇文献进行摘录,所有费用数据均按照2013年我国医疗保健消费价格指数行贴现处理,且以均值表示,同时计算年均增长率。结果最终纳入的32篇文献中,基于住院患者和人群的研究分别有30和2篇;经济负担类型方面,关注直接经济负担、间接经济负担、直接和间接经济负担的文献分别有26、1和5篇;本研究分析结果显示,中国1996—2011年肺癌例均直接医疗费用为10 415~27 595元,年均增长率为2.2%(其中检查费、药品费和化验费用年均增长率分别为3.5%、-3.2%和2.2%);1997—2010年肺癌次均直接医疗费用为9 463~38 209元,年均增长率为-1.7%(其中检查费、药品费和化验费年均增长率分别为16.9%、-2.2%和17.3%);1996—2009年肺癌直接医疗日均费用为426~1 036元,年均增长率为6.3%;直接非医疗费用和间接费用因涵盖项目及方法差异,无法得出趋势数据。结论中国肺癌经济负担研究数据的收集及分析方法不一,例均和次均费用整体趋势不明显,但细化项目多呈增长趋势且幅度不同。Objective To explore the status quo of economic burden of lung cancer in China from 1996 to 2014 and to provide references for further studies and policy making in relation to lung cancer prevention and control. Methods Based on two Chinese publication databases （China National Knowledge Infrastructure [ CNKI ] and Wangfang data- base） and PubMed,literatures focusing on economic burden of lung cancer and published between January 1,1996 and December 31,2 014 were retrieved with the searching words including ＇ cancer＇, ＇ economic burden＇, ＇ cost of illness＇, ＇ expenditure＇ and so on. Then the information were abstracted from the included literatures through a strict inclusion and exclusion process. All the expenditure data were discounted to year of 2013 using China＇ s health care consumer price in- dex （CPI） and an average growth rate per annum （AAGR） was calculated. Results A total of 32 studies were included. The majority of the studies were individual-based （ n = 30） and only two population-based studies were confirmed. The num- bers of studies involving ＇ direct expenditure＇, ＇ indirect expenditure＇, and ＇ direct and indirect expenditure＇ were 26,1 and 5, respectively. The available data suggested that between 1996 and 2011, the direct expenditure per lung cancer pa- tient ranged from 10 415 - 27 595 Chinese Yuan （CNY） and the overall AAGR was 2. 2% （ the AAGR of expenditure on inspection, medicine and laboratory testing were 3.5 %, -3.2% and 2. 2%, respectively ）. The direct expenditure per clinical visit between year 1997 and 2010 ranged from 9 463 to 38 209 CNY;the AAGR of overall,inspection, medicine and laboratory testing were - 1.7%, 16. 9%, -2. 2%, and 17. 3% ,respectively. The estimated expenditure per diem be- tween year 1996 and 2009 ranged from 426 to 1 036 CNY, and the AAGR was 6. 3 %. Time trend of direct non-medical expenditure and indirect medical expenditure could not be clearly described due to the low comparability among the stud- ies. Co

关 键 词：经济负担 肺癌 系统评价 

分 类 号：R734.2[医药卫生—肿瘤]